| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1080/03007995.2017.1335192 |
| P698 | PubMed publication ID | 28537449 |
| P50 | author | Jennifer Goldman | Q88044789 |
| P2093 | author name string | Jeremy Pettus | |
| Tim Heise | |||
| Christoph Kapitza | |||
| P2860 | cites work | Biosimilar insulins: a European perspective | Q27026596 |
| Insulin degludec: Lower day-to-day and within-day variability in pharmacodynamic response compared with insulin glargine 300 U/mL in type 1 diabetes. | Q33835638 | ||
| Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority tria | Q34269828 | ||
| Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority tria | Q34269834 | ||
| Insulin glargine and cancer risk in patients with diabetes: a meta-analysis | Q34320632 | ||
| A review of the pharmacological properties of insulin degludec and their clinical relevance | Q34436383 | ||
| Investigational new insulin glargine 300 U/ml has the same metabolism as insulin glargine 100 U/ml | Q34543063 | ||
| Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes | Q34613075 | ||
| Single-dose new insulin glargine 300 U/ml provides prolonged, stable glycaemic control in Japanese and European people with type 1 diabetes | Q35127583 | ||
| New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2). | Q35240456 | ||
| New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3). | Q35538347 | ||
| Low within- and between-day variability in exposure to new insulin glargine 300 U/ml | Q36361469 | ||
| Patient-level meta-analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml in people with type 2 diabetes | Q36366184 | ||
| One-year sustained glycaemic control and less hypoglycaemia with new insulin glargine 300 U/ml compared with 100 U/ml in people with type 2 diabetes using basal plus meal-time insulin: the EDITION 1 12-month randomized trial, including 6-month exten | Q36366198 | ||
| Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long) | Q36426912 | ||
| A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes | Q36449523 | ||
| Plasma insulin profiles after subcutaneous injection: how close can we get to physiology in people with diabetes? | Q36554243 | ||
| Does insulin glargine increase the risk of cancer compared with other basal insulins?: A French nationwide cohort study based on national administrative databases | Q36560372 | ||
| The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-to-target trial in i | Q36720304 | ||
| Efficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with type 1 diabetes (BEGIN: Flex T1): a 26-week randomized, treat-to-target trial with a 26-week extension | Q36730246 | ||
| Towards peakless, reproducible and long-acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studies | Q36889115 | ||
| Low-volume insulin degludec 200 units/ml once daily improves glycemic control similarly to insulin glargine with a low risk of hypoglycemia in insulin-naive patients with type 2 diabetes: a 26-week, randomized, controlled, multinational, treat-to-ta | Q37106509 | ||
| New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese adults with type 1 diabetes using basal and mealtime insulin: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 1). | Q37343841 | ||
| Basal insulins: Pharmacological properties and patient perspectives | Q37731627 | ||
| How pharmacokinetic and pharmacodynamic principles pave the way for optimal basal insulin therapy in type 2 diabetes | Q37771436 | ||
| A review of modern insulin analogue pharmacokinetic and pharmacodynamic profiles in type 2 diabetes: improvements and limitations | Q37853658 | ||
| Evolution of insulin development: focus on key parameters | Q38030454 | ||
| Insulin stacking versus therapeutic accumulation: understanding the differences. | Q38135295 | ||
| Evolution of insulin: from human to analog | Q38256665 | ||
| Insulin glargine metabolite 21(A) -Gly-human insulin (M1) is the principal component circulating in the plasma of young children with type 1 diabetes: results from the PRESCHOOL study | Q38426608 | ||
| New Insulin Glargine 300 U/mL for the Treatment of Type 1 and Type 2 Diabetes Mellitus | Q38559945 | ||
| Exercise management in type 1 diabetes: a consensus statement | Q39105419 | ||
| Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin. | Q42240405 | ||
| Similar risk of exercise-related hypoglycaemia for insulin degludec to that for insulin glargine in patients with type 1 diabetes: a randomized cross-over trial | Q42383447 | ||
| Basal insulin and cardiovascular and other outcomes in dysglycemia | Q42507791 | ||
| Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes | Q42605636 | ||
| Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: a randomized clinical trial | Q42625907 | ||
| Comparison of insulin detemir and insulin glargine in a basal-bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: a 52-week, multinational, randomized, open-label, parallel-group, treat-to-target noninferior | Q43239421 | ||
| Plasma glucose and hypoglycaemia following exercise in people with Type 1 diabetes: a comparison of three basal insulins | Q43245612 | ||
| Nocturnal blood glucose and IGFBP-1 changes in type 1 diabetes: Differences in the dawn phenomenon between insulin regimens | Q43260302 | ||
| No evidence for accumulation of insulin glargine (LANTUS): a multiple injection study in patients with Type 1 diabetes | Q44024472 | ||
| Biotransformation of insulin glargine after subcutaneous injection in healthy subjects | Q44379874 | ||
| New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1). | Q44485772 | ||
| A comparison of the steady-state pharmacokinetic and pharmacodynamic profiles of 100 and 200 U/mL formulations of ultra-long-acting insulin degludec | Q44599380 | ||
| Efficacy of conversion from bedtime NPH insulin injection to once- or twice-daily injections of insulin glargine in type 1 diabetic patients using basal/bolus therapy | Q44745111 | ||
| Once-daily initiation of basal insulin as add-on to metformin: a 26-week, randomized, treat-to-target trial comparing insulin detemir with insulin glargine in patients with type 2 diabetes | Q45127422 | ||
| Contribution of the dawn phenomenon to the fasting and postbreakfast hyperglycemia in type 1 diabetes treated with once-nightly insulin glargine | Q46060194 | ||
| Reduced risk of hypoglycemia with insulin degludec versus insulin glargine in patients with type 2 diabetes requiring high doses of basal insulin: a meta-analysis of 5 randomized begin trials | Q46129839 | ||
| Efficacy and Safety of Insulin Degludec 200 U/mL and Insulin Degludec 100 U/mL in Patients with Type 2 Diabetes (Begin: Compare). | Q46247786 | ||
| Steady state is reached within 2-3 days of once-daily administration of degludec, a basal insulin with an ultralong duration of action | Q46358093 | ||
| Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes | Q46406475 | ||
| The interpretation of glucose clamp studies of long-acting insulin analogues: from physiology to marketing and back. | Q46452341 | ||
| A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. | Q46458876 | ||
| A randomized multicentre trial of insulin glargine compared with NPH insulin in people with type 1 diabetes | Q46602351 | ||
| Fluctuation and reproducibility of exposure and effect of insulin glargine in healthy subjects | Q46691043 | ||
| Pharmacokinetic and glucodynamic variability: assessment of insulin glargine, NPH insulin and insulin ultralente in healthy volunteers using a euglycaemic clamp technique | Q46701751 | ||
| Comparison of insulin detemir and insulin glargine in subjects with Type 1 diabetes using intensive insulin therapy | Q46707992 | ||
| Insulin detemir results in less weight gain than NPH insulin when used in basal-bolus therapy for type 2 diabetes mellitus, and this advantage increases with baseline body mass index | Q47297341 | ||
| Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes | Q49174475 | ||
| Sustained glycaemic control and less nocturnal hypoglycaemia with insulin glargine 300U/mL compared with glargine 100U/mL in Japanese adults with type 1 diabetes (EDITION JP 1 randomised 12-month trial including 6-month extension). | Q51068494 | ||
| A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes. | Q51552514 | ||
| Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. U.S. Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group. | Q51554474 | ||
| New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 1 Diabetes: A Randomized, Phase 3a, Open-Label Clinical Trial (EDITION 4). | Q53211985 | ||
| Comparison of the Pharmacokinetics and Pharmacodynamics of LY2963016 Insulin Glargine and EU- and US-Approved Versions of Lantus Insulin Glargine in Healthy Subjects: Three Randomized Euglycemic Clamp Studies. | Q53790905 | ||
| Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. | Q55034466 | ||
| The Mechanism of Protraction of Insulin Detemir, a Long-Acting, Acylated Analog of Human Insulin | Q57599459 | ||
| A 26-Week, Randomized, Parallel, Treat-to-Target Trial Comparing Insulin Detemir With NPH Insulin as Add-On Therapy to Oral Glucose-Lowering Drugs in Insulin-Naive People With Type 2 Diabetes | Q59311920 | ||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pharmacokinetics | Q323936 |
| pharmacodynamics | Q725307 | ||
| P304 | page(s) | 1821-1831 | |
| P577 | publication date | 2017-06-23 | |
| P1433 | published in | Current Medical Research and Opinion | Q5195063 |
| P1476 | title | Understanding how pharmacokinetic and pharmacodynamic differences of basal analog insulins influence clinical practice | |
| P478 | volume | 33 |
| Q89484275 | Adjustment of insulin doses when switching from glargine 100 U/ml or detemir to degludec: an observational study |
| Q64904369 | Basal insulin reductions in anticipation of multiple exercise sessions in people with type 1 diabetes-a clinical perspective. |
| Q90206853 | Cost analysis of insulin degludec in comparison with insulin detemir in treatment of children and adolescents with type 1 diabetes in the UK |
| Q92721967 | Differentiating Basal Insulin Preparations: Understanding How They Work Explains Why They Are Different |
| Q92100367 | Glargine-300: An updated literature review on randomized controlled trials and real-world studies |
| Q53448284 | Insulin Matters: A Practical Approach to Basal Insulin Management in Type 2 Diabetes. |
| Q57026285 | Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) |
| Q56979722 | Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) |
| Q92188767 | Nocturnal Glycemic Control with New Insulin Glargine 300 U/mL |
| Q58712651 | Switching From Glargine to Degludec: The Effect on Metabolic Control and Safety During 1-Year of Real Clinical Practice in Children and Adolescents With Type 1 Diabetes |
| Q64039667 | The basal to total insulin ratio in outpatients with diabetes on basal-bolus regimen |
Search more.